轻舟已过万重山，再举云帆万里程，积极把握新一轮产业周期——-2025中报分析之CRO、CDMO医药生物证券研究报告/行业专题报告2025年09月10日评级：增持（维持）重点公司基本状况简称股价2023A2024AEPS2026E2027E2023A2024APE2026E2027E评级（元）分析师：祝嘉琦2025E2025E买入执业证书编号：S0740519040001买入Email：zhujq@zts.com.cn药明康德106.373.343.294.785.236.1731.8532.3322.2520.3417.24买入分析师：崔少煜买入执业证书编号：S0740522060001药明生物37.660.830.820.961.181.4845.3745.9339.2331.9225.45买入Email：cuisy@zts.com.cn买入药明合联64.600.240.891.211.592.06269.1772.5853.3940.6331.36买入买入泰格医药64.662.340.471.251.461.7227.63137.5751.7344.2937.59买入买入康龙化成31.790.901.010...